Gilead Sciences, Inc. (GILD): VRIO Analysis [June-2026 Updated]

This ready-made VRIO Analysis of Gilead Sciences, Inc. gives you a research-based view of how the company creates value through HIV leadership, Biktarvy, long-acting prevention, oncology, Livdelzi, IP protection, AI-enabled R&D, manufacturing, and financial strength as of June 2026. You’ll see which resources create sustained versus temporary competitive advantage, including access across 120-plus countries and a $32B capital plan, making it a practical study aid for essays, case studies, presentations, and business analysis.

Gilead Sciences, Inc. - VRIO Analysis: First Core Capabilities / Resources: HIV franchise and Biktarvy brand leadership

Gilead Sciences' HIV franchise generated $19.6B in 2024 product sales, and Biktarvy generated $13.4B.

Value

Biktarvy drove $13.4B of 2024 sales inside a $19.6B HIV franchise.

Rarity

Biktarvy accounted for 68.6% of HIV product sales in 2024.

Imitability

The commercial base was built over 7 years, from 2018 to 2024.

Organization

Gilead Sciences kept Biktarvy at $13.4B through 2024 execution.

Competitive Advantage

The combination of $19.6B HIV sales and $13.4B Biktarvy sales supports a sustained advantage.

• $19.6B HIV product sales
• $13.4B Biktarvy sales
• 68.6% of HIV product sales from Biktarvy
• 2018-2024 commercial scale build

Gilead Sciences, Inc. - VRIO Analysis: Second Core Capabilities / Resources: Long-acting HIV prevention and treatment platform

Value

The platform adds a 6-month dosing option and sits inside an HIV franchise that generated $19.6 billion in product sales in 2024.

Rarity

This is rare because the U.S. has a first twice-yearly injectable PrEP option, with FDA approval on June 18, 2025.

Imitability

It is hard to copy because it rests on 2 lenacapavir approvals, plus long-acting formulation and regulatory know-how built over multiple years.

Organization

Gilead is organized for this with a 2-indication lenacapavir platform and an HIV commercial base large enough to support launch and scale.

• 2024: HIV product sales of $19.6 billion
• 2025: FDA approval for the first twice-yearly injectable PrEP option
• 6-month dosing interval
• 2 lenacapavir indications

Gilead Sciences, Inc. - VRIO Analysis: Third Core Capabilities / Resources: Oncology development and commercialization engine

Oncology is a temporary VRIO advantage for Gilead because it combines a $21 billion ADC acquisition, a $11.9 billion cell therapy acquisition, and multiple FDA approvals dated April 22, 2020, April 13, 2021, and February 3, 2023.

• $21 billion Immunomedics acquisition in 2020
• $11.9 billion Kite acquisition in 2017
• 2 commercial cell therapy products: Yescarta and Tecartus
• 3 sacituzumab govitecan FDA approval dates: April 22, 2020, April 13, 2021, February 3, 2023

Value

The oncology engine adds non-HIV growth through sacituzumab govitecan and multiple combination-development programs, supported by the $21 billion Immunomedics deal and the $11.9 billion Kite deal.

Rarity

The mix of an ADC asset and 2 marketed cell therapies is uncommon among large biopharma companies.

Imitability

Competitors can build similar assets, but not quickly, because the market entry path runs through multibillion-dollar M&A and multi-year clinical work.

Organization

Gilead has integrated oncology clinical, regulatory, and partnering functions in place across development and commercialization.

Competitive Advantage

Temporary

Gilead Sciences, Inc. - VRIO Analysis: Fourth Core Capabilities / Resources: Inflammation and liver disease franchise via Livdelzi

Value

$4.3 billion and August 14, 2024 created a new specialty liver platform in PBC.

Rarity

1 approved PPAR-delta agonist for PBC in the U.S. gives Gilead a niche position.

Imitability

Replicating a $4.3 billion acquisition plus a 1-product rare-disease launch is hard, but not permanent.

Organization

Gilead has already shown acquisition integration and commercial launch capability in 2024.

• $4.3 billion
• August 14, 2024
• 1
• 2024

Competitive Advantage

Temporary

Gilead Sciences, Inc. - VRIO Analysis: Fifth Core Capabilities / Resources: Intellectual property estate and legal-regulatory expertise

Value

$27.1 billion in 2023 revenue, plus IP-heavy deals worth $11.2 billion in 2011, $11.9 billion in 2017, and up to $21.0 billion in 2020, shows direct cash value from exclusivity, pricing power, and monetization.

Rarity

The mix of patent assets, licensing reach, and dispute execution is uncommon: a license covering 91 countries with 11 generic manufacturers, plus a $2.54 billion Merck patent settlement in 2017.

Imitability

Hard to copy because the position was assembled over 2011, 2017, and 2020, and reinforced by a $2.54 billion settlement record that newer rivals do not have.

• $11.2 billion Pharmasset acquisition in 2011
• $11.9 billion Kite Pharma acquisition in 2017
• Up to $21.0 billion Immunomedics acquisition in 2020
• $2.54 billion Merck patent settlement in 2017
• 91 countries and 11 generic manufacturers in the license structure

Organization

Gilead Sciences, Inc. has shown the legal, compliance, and regulatory capacity to convert IP into enforceable economics through transactions of $11.2 billion, $11.9 billion, and $21.0 billion, plus a $2.54 billion settlement.

Competitive Advantage

Sustained through $27.1 billion revenue, 91-country licensing reach, and $2.54 billion litigation leverage.

Gilead Sciences, Inc. - VRIO Analysis: Sixth Core Capabilities / Resources: Global commercialization and access network

Gilead Sciences, Inc.'s access network reaches 120 countries through 6 generic manufacturers, which makes the resource valuable and difficult to copy quickly.

Value

Coverage across 120 countries extends patient reach and market access beyond direct commercial sales.

Rarity

A broad HIV access structure tied to 120 countries is rare.

Inimitability

Replicating a network built around 120 countries and 6 generic manufacturers needs country-by-country relationships and infrastructure.

Organization

• 120 countries
• 6 generic manufacturers

Competitive Advantage

Sustained.

Gilead Sciences, Inc. - VRIO Analysis: Seventh Core Capabilities / Resources: AI-enabled R&D and drug discovery engine

Value

Gilead’s AI-linked discovery effort is tied to a $32B capital plan and a 2024 Genesis collaboration, which supports faster target identification, molecule design, and pipeline screening.

Rarity

At Gilead’s scale, pairing a $32B capital plan with external AI discovery partnerships is uncommon.

Imitability

It is hard to copy without comparable data, scientific talent, compute capacity, and wet-lab integration across the R&D stack.

Organization

Gilead appears organized to use this capability through the Genesis collaboration, a new technical center, and the $32B capital plan.

• $32B capital plan supports continued investment.
• 2024 Genesis collaboration adds external AI capability.
• New technical center supports internal execution.

Gilead Sciences, Inc. - VRIO Analysis: Eighth Core Capabilities / Resources: Manufacturing and technical development infrastructure

Gilead's manufacturing and technical development infrastructure is a sustained advantage because it supports 2 marketed CAR-T therapies and was built through large transactions, including $11.9 billion in 2017, $21.0 billion in 2020, and $4.3 billion in 2024.

Value

This resource improves supply reliability, quality control, launch readiness, and cost efficiency for complex therapies that depend on validated production and technical transfer.

Rarity

Large-scale, compliant biopharma manufacturing capacity is difficult to assemble, and Gilead's 2 marketed CAR-T therapies show a narrower capability set than most large drugmakers.

Imitability

It is hard to imitate because the capability requires capital intensity, regulatory standards, and years of operational experience, reflected in acquisitions of $11.9 billion, $21.0 billion, and $4.3 billion.

Organization

• 2017: Kite Pharma acquisition for $11.9 billion.
• 2020: Immunomedics acquisition for $21.0 billion.
• 2024: CymaBay acquisition for $4.3 billion.
• 2 marketed CAR-T therapies.

Gilead has organized capital and development around these assets through U.S. investment, technical development expansion, and global operations.

Competitive Advantage

Sustained.

Gilead Sciences, Inc. - VRIO Analysis: Ninth Core Capabilities / Resources: Financial strength and capital allocation capacity

Value

$10.2 billion; $3.08; $21.0 billion.

Rarity

$10.2 billion; not rare among large pharma.

Inimitability

$9.5 billion; $4.3 billion.

Organized

$21.0 billion; $9.5 billion; $4.3 billion; $0.77.

Competitive Advantage

Temporary.